Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward
Portfolio Pulse from
Olema Pharmaceuticals has entered into a supply agreement with Novartis for KISQALI, supporting its upcoming phase 3 OPERA-02 study for ER+/HER2- metastatic breast cancer. The study is set to begin in mid-2025, with data from another ongoing study expected in 2026.
December 02, 2024 | 9:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Olema Pharmaceuticals has secured a supply agreement with Novartis for KISQALI, which will be used in its upcoming phase 3 OPERA-02 study for breast cancer, starting mid-2025.
The agreement with Novartis provides Olema with a critical component for its upcoming study, potentially enhancing its research capabilities and future market position in the breast cancer treatment space.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
NEUTRAL IMPACT
Novartis has entered into a supply agreement with Olema Pharmaceuticals to provide KISQALI for a phase 3 study targeting breast cancer, starting mid-2025.
While the agreement with Olema highlights Novartis's role in supporting cancer research, it is a small part of its broader operations, thus having a neutral short-term impact on its stock.
CONFIDENCE 85
IMPORTANCE 50
RELEVANCE 60